Acceleron recently announced that treatment with ACE-083 in patients with CMT did not demonstrate functional improvement in the Phase 2 trial.  ACE-083 is a drug which is injected locally into a muscle in order to stimulate growth of the injected muscle. Although ACE-083 did show a significant increase in the size of the tibialis anterior muscle in the lower leg, this increase did not translate to significant improvements in any of the functional or quality of life measurements when compared to placebo. As a result, Acceleron is discontinuing development of ACE-083.

Read the full press release from Acceleron.